Quantcast

Latest Carl June Stories

2014-06-04 08:30:08

ANN ARBOR, Mich., June 4, 2014 /PRNewswire-USNewswire/ -- A physician-scientist who developed a personalized immunotherapy for leukemia using patients' own T cells is the recipient of the 2014 Taubman Prize for Excellence in Translational Medical Science, awarded by the A. Alfred Taubman Medical Research Institute at the University of Michigan Medical School. Carl June, M.D. of the Perelman School of Medicine at the University of Pennsylvania will receive the $100,000 prize in...

2014-05-17 23:03:27

A professor of immunology at the University of Pennsylvania’s Perelman School of Medicine, Dr. Carl June gave a captivating description of the promise of immunology therapy during a presentation Wednesday, May 14 at UC San Diego. La Jolla, CA (PRWEB) May 17, 2014 For Dr. Carl June, lead researcher of a promising anti-cancer therapy known as immunology, the future looks brighter for those afflicted with cancer, based on early results from his clinical trials on a relatively small handful...

2014-04-04 23:27:07

Immunotherapy is one of the most exciting new approaches to treating cancer. Dr. Carl June will discuss his findings May 14 as featured speaker at UC San Diego. (PRWEB) April 04, 2014 A world leader in immunotherapy, Carl June, will discuss the emergence of a new form of targeted immunotherapy to treat cancer, Wednesday, May 14, 5:30 pm to 7 pm., at UC San Diego. June, professor of immunotherapy at the University of Pennsylvania, will discuss his pioneering work and also the barriers and...

2013-12-27 12:22:29

Non-profit provides tens of millions in grants since founding by Barbara and Edward Netter in 2001 STAMFORD, Conn., Dec. 27, 2013 /PRNewswire/ -- As the potential of gene and cell therapy in fighting cancers grows and oncologists across the nation explore the burgeoning science, doctors have uncovered a stunning development - cancers can be treated using patients' own cells as a weapon, and can eliminate the harrowing, often debilitating effects of chemotherapy, radiation and surgery. (Photo:...

2013-05-09 23:45:40

The Cancer Research Institute (CRI) declares June “Cancer Immunotherapy Awareness Month” to increase awareness of cancer immunotherapy, a new class of cancer treatment that mobilizes the immune system to fight the disease and represents the most immediate hope for curing patients with any type of cancer. The month will feature educational webinars offered free to the public from top experts in cancer immunotherapy, and a Wear White for a Cure Day on June 7. New York, NY (PRWEB)...

2012-05-02 21:16:21

Results open up field of T cell gene therapy for use in other diseases HIV patients treated with genetically modified T cells remain healthy up to 11 years after initial therapy, researchers from the Perelman School of Medicine at the University of Pennsylvania report in the new issue of Science Translational Medicine. The results provide a framework for the use of this type of gene therapy as a powerful weapon in the treatment of HIV, cancer, and a wide variety of other diseases. "We...

2011-08-10 22:55:44

Gene therapy approach provides tumor-attack roadmap for other cancers In a cancer treatment breakthrough 20 years in the making, researchers from the University of Pennsylvania's Abramson Cancer Center and Perelman School of Medicine have shown sustained remissions of up to a year among a small group of advanced chronic lymphocytic leukemia (CLL) patients treated with genetically engineered versions of their own T cells. The protocol, which involves removing patients' cells and modifying them...

2011-03-03 06:00:00

RICHMOND, Calif., March 3, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that data from its programs to develop ZFN-based therapeutic approaches for the treatment of HIV/AIDS were discussed in four oral presentations at the 18th Conference on Retroviruses and Opportunistic Infections (CROI), held in Boston from February 27 to March 2, 2011. "SB-728-T is a key addition to the toolbox of technologies required to move from the bone marrow transplant setting...

2011-02-28 07:30:00

RICHMOND, Calif., Feb. 28, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of positive preliminary clinical data from its Phase 1 trial (SB-728-902). The trial is being conducted in immunologic non-responders, HIV-infected subjects who are currently on highly active antiretroviral therapy (HAART) and have undetectable levels of virus but suboptimal CD4+ T-cell counts. The study is designed to evaluate safety and clinical outcomes of...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'